Focus on underserved niche markets, including hospital acute care and gastroenterology, we supply products that offer distinct advantages over prior treatments. Our commitment to excellence propels us on our mission of providing innovative products that address poorly met medical needs.
CryoCrate
CryoCrate is an NIH Innovation Showcase company advancing next-generation tissue cryopreservation and tissue engineering technologies, supported by 12 NIH and DoD awards. The company has developed a first-in-class biocompatible preservation platform based on proprietary nano ice formation and glycocalyx-mediated mechanisms. Unlike conventional approaches, CryoCrate’s polysaccharide-based formulation is free of small-molecule permeating cryoprotectants, enabling preservation without compromising structural integrity or cellular function. This platform supports cryopreservation of ocular tissues, particularly corneal grafts, as well as skin and a wide range of cell types for transplantation and clinical biobanking. In parallel, its glycocalyx-targeted approach enhances wound healing and supports tissue engineering applications, positioning CryoCrate at the intersection of regenerative medicine and transplantation.
CorMedix Therapeutics
Melinta Therapeutics provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes seven commercial-stage products. With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information. | At CorMedix Therapeutics, we’re driven to protect vulnerable patients from serious, life-threatening infections. With eight commercial-stage products spanning prevention and treatment, we address critical, unmet needs across multiple care settings. Our dedicated team is committed to ensuring access to our therapies and to continuously expanding our portfolio to improve patient outcomes. Discover more at www.cormedix.com
Colgate Oral Pharmaceuticals
Colgate-Palmolive is the global leader in oral care technology, products, and education. Colgate s products include technologically advanced toothpastes, toothbrushes, mouth rinses, and floss. Our Colgate Oral Pharmaceuticals subsidiary provides professional fluoride, gingival health, and tooth whitening products. Please visit our booth for additional information and an overview of our complete line of professional products.
Colgate-Palmolive Canada
Colgate-Palmolive is the global leader in Oral Care Technology, products and education. Colgate’s products include technologically advanced toothpastes, toothbrushes, mouth rinses and floss. Visit our booth for additional information and an overview of our complete line of professional products. Smile first, and let your confidence do the talking!
Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting bacterial biofilms. The Columbus, Ohio-based company is building a pipeline of immune-enabling medicines, including CMTX-101, which completed a positive Phase 2 study in cystic fibrosis patients in early 2026, and plans to pursue additional mid-stage studies in other chronic respiratory diseases including bronchiectasis. The company’s second program, CMTX-301, is in early development to evaluate the technology in a preventive approach. | Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory disease decline through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2a study for infections associated with cystic fibrosis, and CMTX-301, an anti-biofilm vaccine in early development.
China Eye Valley
China Eye Valley is a national-level ophthalmic innovation ecosystem based in Wenzhou, China, integrating research, clinical care, industry, and investment. Anchored by the Wenzhou Medical University Eye Hospital, it supports the full pipeline from basic research to commercialization. The platform hosts over 400 eye health enterprises and offers advanced capabilities in biomaterials, medical devices, AI-driven diagnostics, and real-world evidence (RWE) studies. At ARVO, China Eye Valley showcases its collaborative model and seeks global partnerships to accelerate innovation, regulatory advancement, and market access in ophthalmology.
China Anti-Cancer Association
China Anti-Cancer Association (CACA) is a non-governmental and non-profit organization in the field of oncology in China. Founded in 1984, it has developed into the largest organization in cancer field with long history and great influence in China. Up to now, CACA has established local anti-cancer associations in all 31 provinces, cities, and autonomous regions across China, creating a network of 200 professional societies. With 162 organization members and over 800,000 individual members, CACA serves as a significant platform for academic exchanges, public education, promoting CACA Guidelines, and international cooperation in the field of oncology.
ChemPartner
Over the past twenty years, ChemPartner has evolved from a pure chemistry service provider to a research innovation engine with a broad portfolio of services spanning from discovery through development in both small molecule and large molecule therapeutics.
Charles River
Charles River is a global preclinical oncology CRO delivering end to end oncology and immuno oncology drug discovery, from target identification and validation through IND enabling and clinical. We partner with academic, biotechnology, and pharmaceutical companies to advance innovative cancer therapies. In 2025, Charles River supported 87% of FDA-approved oncology therapies, including first-in-class and best-in-class drugs. Our capabilities span small molecules, biologics, antibodies, antibody drug conjugates (ADCs), immunotherapies, checkpoint inhibitors, cell therapies, and gene therapies. Our research model (RMS) portfolio includes immunodeficient mice and rats, PBMC and CD34+ humanized mouse models, end-to-end support from colony management for Genetically Engineered Model (GEM), including transgenic model generation and breeding, to vivarium rental or customizable onsite services (staffing, consulting, training), and CRADL® support in global biohubs. Our oncology platforms include 1,700+ xenograft models (PDX, CDX, syngeneic, humanized), covering 45+ cancer indications across solid tumors, hematologic, and pediatric cancers. Integrated in vitro, ex vivo, NAMs and 3D tumor models—including organoids, tumoroids, and tissue microarrays (TMAs)- support efficacy, PK/PD, biomarker, and translational decision making. Multi omics, AI enabled analytics, and strategic CMC/CDMO capabilities help teams plan manufacturing earlier, strengthen regulatory readiness, improve study design, reduce risk, and accelerate candidate to patients. Learn more at criver.com/cancer-research-annual-meeting-2026 | Charles River has supported researchers in advancing ocular therapies for more than two decades, with a comprehensive suite of capabilities designed to meet your program needs. We help you progress small molecules, biologics, gene and cell therapies, and implantable devices from concept to clinic with confidence. Our team provides rigorous efficacy, distribution, and safety assessments supported by state-of-the-art imaging, functional evaluations, and New Approach Methodologies (NAMs) to help you improve predictability and generate high-quality data for global regulatory submissions. We also assess the ocular effects of systemic compounds for non-ocular indications, helping you refine study design, manage timelines and resources, and reduce animal use. We are committed to partnering with you at every stage to help bring meaningful treatments to patients worldwide because every moment matters. | Charles River provides essential products and services to support pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide in accelerating research and drug development. As a leader in scientific innovation, we are deeply committed to pioneering alternative methods that drive discovery while reducing reliance on traditional models. By embracing cutting-edge technologies and forward-thinking approaches, we enhance preclinical and clinical research. Our dedicated employees focus on delivering precisely what our clients need to improve, innovate, and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients—because every moment matters. Learn more at www.criver.com. | Charles River is committed to helping companies like yours get your product to market safely and efficiently. Whether you’re still in development or already manufacturing, our Safety Assessment and Microbial Solutions services provide state-of-the-art technology and expert regulatory advice that will help you anticipate challenges, avoid roadblocks, and make better decisions.